Can-Fite BioPharma Ltd. (CANF)

3.00
0.04 1.35
AMEX : Health Technology
Prev Close 2.96
Open 2.98
Day Low/High 2.86 / 3.10
52 Wk Low/High 0.38 / 25.95
Volume 130.50K
Avg Volume 546.40K
Exchange AMEX
Shares Outstanding 1.82M
Market Cap 10.71M
EPS -5.00
P/E Ratio 1.16
Div & Yield N.A. (N.A)

Latest News

Can-Fite Announces Preparation For End-of-Phase II Meeting With FDA To Initiate The Phase III Liver Cancer Study For Namodenoson

Can-Fite Announces Preparation For End-of-Phase II Meeting With FDA To Initiate The Phase III Liver Cancer Study For Namodenoson

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today it is conducting preparatory work for a planned...

Can-Fite Announces ADS Ratio Change

Can-Fite Announces ADS Ratio Change

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that the Company will change the ratio of its...

Can-Fite Receives $1,000,000 Payment From CKD For Distribution Of Namodenoson In South Korea

Can-Fite Receives $1,000,000 Payment From CKD For Distribution Of Namodenoson In South Korea

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today it has received a $1,000,000 payment from Chong Kun...

Can-Fite Announces Late-Breaking Abstract Presentation On Namodenoson™ Phase II Results At The American Association Of Clinical Oncology (ASCO) Annual Meeting

Can-Fite Announces Late-Breaking Abstract Presentation On Namodenoson™ Phase II Results At The American Association Of Clinical Oncology (ASCO) Annual Meeting

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that a late-breaking abstract detailing results from...

Can-Fite BioPharma Announces $3.2 Million Registered Direct Offering

Can-Fite BioPharma Announces $3.2 Million Registered Direct Offering

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI) , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered into a definitive...

Can-Fite Files Annual Report For The Year Ended December 31, 2018

Can-Fite Files Annual Report For The Year Ended December 31, 2018

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that it has filed its annual report on Form...

Can-Fite Reports 2018 Financial Results & Provides Clinical Update

Can-Fite Reports 2018 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced financial results for the year ended December...

Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results For Its Orphan/Fast Track Drug Namodenoson

Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results For Its Orphan/Fast Track Drug Namodenoson

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that the Phase II advanced liver cancer study did not...

Can-Fite To Participate In Bio Asia International Conference On March 5-6, 2019 In Tokyo

Can-Fite To Participate In Bio Asia International Conference On March 5-6, 2019 In Tokyo

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the Company's VP of Business...

Can-Fite Expands Its Namodenoson Distribution Deal With CKD In South Korea With NASH Indication

Can-Fite Expands Its Namodenoson Distribution Deal With CKD In South Korea With NASH Indication

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the expansion of its distribution agreement...

Can-Fite Receives Notice Of Allowance From U.S. Patent And Trademark Office For Osteoarthritis Drug

Can-Fite Receives Notice Of Allowance From U.S. Patent And Trademark Office For Osteoarthritis Drug

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has received a Notice of Allowance...

Can-Fite's Drugs' Potential Ability To Treat Cytokine Release Syndrome In Cancer Immunotherapy Published In Scientific Journal

Can-Fite's Drugs' Potential Ability To Treat Cytokine Release Syndrome In Cancer Immunotherapy Published In Scientific Journal

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that Drug Design, Development and Therapy has...

Can-Fite BioPharma CEO Letter To Shareholders

Can-Fite BioPharma CEO Letter To Shareholders

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that Pnina Fishman, Chief Executive Officer...

Can-Fite BioPharma Announces Registered Direct Offering

Can-Fite BioPharma Announces Registered Direct Offering

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI) , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered into a definitive...

Can-Fite: Pre-Clinical Data Positions Namodenoson As An Anti-Obesity Agent

Can-Fite: Pre-Clinical Data Positions Namodenoson As An Anti-Obesity Agent

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced new pre-clinical findings demonstrating that...

Can-Fite To Participate In The Biotech Showcase™ 2019 And BIO One-on-One Partnering™@ JPM 2019 During The JP Morgan Healthcare Conference

Can-Fite To Participate In The Biotech Showcase™ 2019 And BIO One-on-One Partnering™@ JPM 2019 During The JP Morgan Healthcare Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it will participate at the Biotech...

Can-Fite Enters Into Collaboration Agreement To Explore Namodenoson's Anti-NASH Effect With Icahn School Of Medicine At Mount Sinai In NYC

Can-Fite Enters Into Collaboration Agreement To Explore Namodenoson's Anti-NASH Effect With Icahn School Of Medicine At Mount Sinai In NYC

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced a collaborative research agreement with the Icahn...

Can-Fite Reports Third Quarter 2018 Financial Results And Provides Clinical Development Update

Can-Fite Reports Third Quarter 2018 Financial Results And Provides Clinical Development Update

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today reported financial results for the nine months...

Prior To Phase II Liver Cancer Data Release Can-Fite Brings On Board An Oncologist Expert

Prior To Phase II Liver Cancer Data Release Can-Fite Brings On Board An Oncologist Expert

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced that Professor Josep Llovet, an experienced leader with deep...

Due To Patient Survival, Top Line Results Of The Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19

Due To Patient Survival, Top Line Results Of The Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver, and inflammatory diseases, today provided an update on its Phase II clinical trial of...

Can-Fite To Present On Its Liver Cancer Drug Namodenoson At The NYC Oncology Investor Conference

Can-Fite To Present On Its Liver Cancer Drug Namodenoson At The NYC Oncology Investor Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver and inflammatory diseases, today announced that its CEO, Dr.

Can-Fite CEO To Present As Expert Speaker On Namodenoson At NASH Summit Europe 2018

Can-Fite CEO To Present As Expert Speaker On Namodenoson At NASH Summit Europe 2018

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver and inflammatory diseases, today announced that its CEO, Dr.

Can-Fite To Present The Anti-Fibrogenic Effects Of Namodenoson At The Hepatic Fibrosis Conference Of The American Association For The Study Of Liver Diseases (AASLD)

Can-Fite To Present The Anti-Fibrogenic Effects Of Namodenoson At The Hepatic Fibrosis Conference Of The American Association For The Study Of Liver Diseases (AASLD)

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today announced its poster presentation of the...

Top Line Results Of The Namodenoson Phase II Advanced Liver Cancer Trial Expected By End Of Year

Top Line Results Of The Namodenoson Phase II Advanced Liver Cancer Trial Expected By End Of Year

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its Phase II clinical trial of...

Can-Fite Reports Second Quarter 2018 Financial Results And Provides Clinical Update

Can-Fite Reports Second Quarter 2018 Financial Results And Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today reported financial results for the three months...

Can-Fite BioPharma Announces Participation At The 20th Annual Global Investment Conference In New York City September 4-6, 2018

Can-Fite BioPharma Announces Participation At The 20th Annual Global Investment Conference In New York City September 4-6, 2018

Can-Fite BioPharma (CANF), today announced it will be featured as a presenting company at the 20 th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.

Can-Fite Announces Enrollment Of First Patient In Its Comfort™ Phase III Trial Of Piclidenoson In Psoriasis

Can-Fite Announces Enrollment Of First Patient In Its Comfort™ Phase III Trial Of Piclidenoson In Psoriasis

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the first patient has been enrolled and dosed...

Can-Fite Receives From CMS Medical Venture Investment Limited $2,000,000 Upfront Payment As Part Of Development, Registration And Marketing Agreement For Piclidenoson And Namodenoson In China

Can-Fite Receives From CMS Medical Venture Investment Limited $2,000,000 Upfront Payment As Part Of Development, Registration And Marketing Agreement For Piclidenoson And Namodenoson In China

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has received its first payment of...

TheStreet Quant Rating: E+ (Sell)